Xilio Therapeutics is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. These molecules are designed to localize activity within the tumor microenvironment without systemic effect, resulting in the potential to achieve enhanced anti-tumor activity. Xilio is building a pipeline of wholly owned, tumor-selective, GPS-enabled cytokine and checkpoint inhibitor product candidates, including XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody; XTX202, a tumor-selective IL-2; XTX301, a tumor-selective IL-12; and XTX401, a tumor-selective IL-15.
Xilio was founded in 2016 and is headquartered in Waltham, Mass. For more information, please visit www.xiliotx.com
Xilio Therapeutics, Inc. today announced the closing of its previously announced initial public offering of 7,353,000 shares of its common stock at a price to the public of $16.00 per share
2021/02/24• Deal led by Rock Springs Capital and joined by Bain Capital Life Sciences, Deerfield Management, RA Capital Management and other investors
• Proceeds will advance XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4) into the clinic
• Two investigational new drug (IND) applications planned in 2021
2020/11/12Xilio Therapeutics today announced the presentation of preclinical data of its lead investigational therapies at the 35th Annual Meeting of The Society for Immunotherapy of Cancer (SICT 2020).
Mr. Clancy brings significant strategic, financial and operational leadership experience in the biotechnology and pharmaceutical industry
To Lead XTX201 (Tumor-Selective IL-2) and XTX101 (Tumor-Selective aCTLA-4) into the Clinic while Xilio Continues to Advance its Tumor-Selective Cytokine Pipeline
